This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.

Advertisement Advertisement Advertisement Advertisement
Text Version  RSS  Subscribe  Unsubscribe  Archive  Media Kit November 28, 2014
Home    About AST    Education    Meetings & Events    Public Policy    Contact Us  



Watch webinars online, anytime
AST has a variety of recorded webinars available for viewing online 24/7. The most recent archived webinars include WTC 2014 highlights, Kidney Allocation System changes, and vaccine updates; all are available at

Visit to choose from more than 30 webinars on topics ranging from Hepatitis C management to living donor advocacy to infectious disease guidelines.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

COP contribution contest
The AST Board presents a COP Contribution Contest to all AST members who participate in one or more Communities of Practice. The board will award a prize to the COP with the highest percentage of contributing members during this time: $2,000 towards a COP initiative in 2015 (must be approved by the AST Board of Directors).

For more details, click here.

To improve our external fundraising efforts, we must first improve our internal philanthropy. We encourage all AST members to donate to the AST before the end of 2014. The amount is not crucial, but achieving high participation rates are of paramount importance:

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

You care about your transplant patients. And so do we. That’s why we’re introducing Astellas Cares—a new program that offers you customized tools, educational resources, and comprehensive support to help your patients care for their health. To register, visit today.


Deeply discounted early registration rates - ends Nov. 30
The Cutting Edge of Transplantation
Immunity and Inflammation: Engineering Cell, Gene, and Drug Therapies

Feb. 5-7, 2015
Sheraton Wild Horse Pass – Chandler, Arizona

Time is running out to take advantage of deep discounts on registration for CEOT. Register by Nov. 30 to enjoy heavily discounted rates. These early registration rates are the lowest rates that will be available for this meeting. Make plans to attend this high-energy, intimate meeting where expert clinicians, leading diagnosticians, and world class scientists will address the field’s cutting edge challenges together with an engaged audience.

This year’s CEOT will feature talks on:
  • Tregs: What is the Promise of Cell Therapy Today?
  • Promising New Drugs in Other Fields: Best in Rheumatology, Inflammatory Bowel Disease & Cancer Immunology
  • Adding Value: The Approach to Repurposing Drugs
  • Novel Approaches to Modifying the Genome
  • Genetic Manipulation to "Supercharge" T Cells
  • Novel Therapeutic Strategies for Regenerative Medicine
  • Differentiation of Stem Cells in 3-D
Click here to register for CEOT 2015 and take advantage of early registration discounted rates! Or, learn more about this engaging meeting and view the preliminary program here.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Pancreas transplantation with enteroanastomosis to native duodenum poses technical challenges—but offers improved endoscopic access for scheduled biopsies and therapeutic interventions
American Journal of Transplantation
To facilitate endoscopic access for rejection surveillance and stenting of the pancreas, this study abandoned the duodenojejunostomy (DJ) in favor of duodenoduodenostomy (DD) in pancreas transplantation (PTx). From September 2012 to September 2013 we performed 40 PTx with DD; 20 solitary-PTx (S-PTx) and 20 simultaneous pancreas and kidney transplantation (SPK). The study compared the outcomes with results from 40 PTx-DJ (10 S-PTx and 30 SPK) from the preceding era. The DD-enteroanastomoses were performed successfully.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Survival benefit of repeat liver transplantation in the United States: A serial MELD analysis by hepatitis C status and donor risk index
American Journal of Transplantation
Survival benefit (SB) for first liver transplantation (LT) is favorable at Model for End-Stage Liver Disease (MELD) ≥15. Herein, we identify the MELD threshold for SB from repeat liver transplantation (ReLT) by recipient hepatitis C virus (HCV) status and donor risk index (DRI). This study analyzed lab MELD scores in new United Network for Organ Sharing registrants for ReLT from March 2002 to January 2010.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Raptor's mission is to develop and commercialize life-altering therapeutics that treat rare, debilitating, and often fatal diseases.
Advertise here!

To find out how to feature your company in the AST eNewsletter and other advertising opportunities, Contact Tom Crist at 972-402-7724.

Early donor-specific antibodies in lung transplantation: Risk factors and impact on survival
The Journal of Heart and Lung Transplantation
The impact of early donor-specific anti-HLA antibodies (DSA) on patient and graft survival after lung transplantation remains controversial. In this study we analyzed risk factors for DSA that developed before initial hospital discharge after lung transplantation (early DSA) and compared mid-term outcomes in patients with or without DSA.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

  UCLA Immunogenetics Center

The UCLA Immunogenetics Center (UIC) provides comprehensive testing for organ and tissue transplantation. Transplant testing has a long history at UCLA. HLA typing was pioneered here in the 1960's. The development of the microcytoxicity test in 1964 marked the beginning of international testing and standardization of HLA typing. The UCLA Immunogenetics Center has retained its leadership position in HLA research, and in the development of accompanying diagnostic testing. MORE

Quality of life and metrics of achievement in long-term adult survivors of pediatric heart transplant
Pediatric Transplantation
Many children who undergo heart transplantation will survive into adulthood. This study sought to examine the QOL and capacity for achievement in long-term adult survivors of pediatric heart transplantation. Adults >18 yr of age who received transplants as children (≤18 yr old) and had survived for at least 10 yr post-transplant completed two self-report questionnaires: (i) Ferrans & Powers QLI, in which life satisfaction is reported as an overall score and in four subscale domains and is then indexed from 0 (very dissatisfied) to 1 (very satisfied); and (ii) a "Metrics of Life Achievement" questionnaire regarding income, education, relationships, housing status, and access to healthcare.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Intellectual and academic performance in children undergoing solid organ pretransplant evaluation
Pediatric Transplantation
Although prior research has shown lower intellectual functioning across pediatric solid organ transplant recipients relative to matched siblings or norm comparisons, few studies have assessed intellectual and academic performance prior to transplant across organ groups. The current data examine intellectual and academic functioning in children being evaluated for kidney, liver, or heart transplant. This investigation included intellectual and academic testing data from 195 children and adolescents between the ages of six and 19 year evaluated for solid organ transplantation.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation
The Journal of Heart and Lung Transplantation
Bronchiolitis obliterans syndrome (BOS) is the major cause of late graft failure after lung transplantation. The objective was to determine whether de novo donor human leukocyte antigen (HLA)-specific antibodies (DSA) are associated with the development of BOS or patient survival. Data were analyzed from 188 lung transplant recipients with a follow-up period up to 8 years.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Have risk factors for mortality after heart transplantation changed over time? Insights from 19 years of Cardiac Transplant Research Database study
The Journal of Heart and Lung Transplantation
The Cardiac Transplant Research Database (CTRD) collected data from 26 U.S. institutions from Jan. 1, 1990 to Dec. 31, 2008 providing the opportunity for construction of a comprehensive multivariable model of risk for death after transplantation. This study analyzed risk factors for death over 19 years of experience to determine how risk profiles have changed over time and how they interact with age.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Missed last week's issue? See which articles your colleagues read most.

    A complete treatment of adult living donor liver transplantation: A review of surgical technique and current challenges to expand indication of patients (American Journal of Transplantation)
Donor-specific antibodies in allograft recipients: Etiology, impact, and therapeutic approaches (Current Opinion in Organ Transplantation)
An interferon-free antiviral regimen for HCV after liver transplantation (The New England Journal of Medicine)
Actual and perceived knowledge of kidney transplantation and the pursuit of a live donor (Transplantation)

Don't be left behind. Click here to see what else you missed.

AST eNews

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Julie Bernhard, Executive Editor, 469.420.2647  
Contribute news

This edition of the AST eNews was sent to ##Email##. To unsubscribe, click here.

Recent issues
Nov. 21, 2014
Nov. 14, 2014
Nov. 7, 2014
Oct. 31, 2014

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063